Alexion is preparing filings in major markets for its rare disease drug Soliris in a new indication after a positive readout in a rare neurological disease.
Alexion's rare disease drug Soliris is generating blockbuster-level sales – but the US biotech is rushing through development of a successor amid potential competition and U